-
Mashup Score: 5Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer - PubMed - 19 day(s) ago
We aimed to study the incidence and genomic spectrum of actionable alterations (AA) detected in serial cfDNA collections from patients with metastatic breast cancer (MBC). Patients with MBC who underwent plasma-based cfDNA testing (Guardant360®) between 2015 and 2021 at an academic instit …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 52Pig Day - 2 month(s) ago
What do Miss Piggy and Olivia all have in common? They are loved by the kids at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Their love of pigs is celebrated each year at the Center’s Pig Party. This year marked the party’s sixth year.
Source: www.jimmyfund.orgCategories: General Medicine News, Hem/OncsTweet-
Today we celebrate Jimmy Fund - Pig Day https://t.co/TnrXSW7Wj6 via @TheJimmyFund #pigday https://t.co/Pe7oeRsdm3
-
-
Mashup Score: 80Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− metastatic breast cancer? - 5 month(s) ago
Author links open overlay panel A. Giordano 1 2 3, N.U. Lin 1 2 3, S.M. Tolaney 1 2 3, E.L. Mayer 1 2 3 AG reports an advisory role for Pfizer. NUL reports consulting honoraria from Puma, Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Denali Therapeutics, Prelude Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, Blueprint Medicines, Stemline/Menarini, and Artera Inc.; and institutional research support fro m Genentech, Pfizer, Merck, Seattle
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Our article is now available online @Annals_Oncology Prologue to #SABCS23 Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− #MBC? @elmayermd @stolaney1 @nlinmd @DFCI_BreastOnc #bcsm https://t.co/ZiAzmnt1Ij
-
-
Mashup Score: 77Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− metastatic breast cancer? - 5 month(s) ago
Author links open overlay panel A. Giordano 1 2 3, N.U. Lin 1 2 3, S.M. Tolaney 1 2 3, E.L. Mayer 1 2 3 AG reports an advisory role for Pfizer. NUL reports consulting honoraria from Puma, Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Denali Therapeutics, Prelude Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, Blueprint Medicines, Stemline/Menarini, and Artera Inc.; and institutional research support fro m Genentech, Pfizer, Merck, Seattle
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Our article is now available online @Annals_Oncology Prologue to #SABCS23 Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− #MBC? @elmayermd @stolaney1 @nlinmd @DFCI_BreastOnc #bcsm https://t.co/ZiAzmnt1Ij
-
-
Mashup Score: 5Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis - PubMed - 6 month(s) ago
Effective policy and interventions have resulted in decreased proportions of women diagnosed with metastatic breast cancer at diagnosis in high-income countries, yet inequality persists, which needs to be addressed through increased awareness of breast cancer symptoms and early detection. Improving …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Effective policy and interventions resulted in ⬇️ diagnosed of metastatic breast cancer in high-income countries, yet inequality persists (eg. in Africa), which needs to be addressed through increased awareness of symptoms and early detection @darioT_ https://t.co/Ry4aR53ceg
-
-
Mashup Score: 1Changes in methylation-based aging in women who do and do not develop breast cancer - 9 month(s) ago
AbstractBackground. Breast cancer survivors have increased incidence of age-related diseases, suggesting that some survivors may experience faster biological ag
Source: academic.oup.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Changes in methylation-based aging in women who do and do not develop breast cancer: Biological aging is accelerated following a breast cancer diagnosis and Breast cancer treatment modalities https://t.co/bDQIERqhdb
-
-
Mashup Score: 0
Palbociclib was not effective at treating nonbreast solid tumors with a CCND1, 2, or 3 amplification in this cohort. These data do not support further investigation of single-agent palbociclib in tumors with CCND1, 2, or 3 amplification.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
No responses with Palbociclib in nonbreast tumors with a CCND1, 2, or 3 amplification in NCI-MATCH. These data do not support further investigation of single-agent palbo in tumors with CCND1, 2, or 3 amplification. Other CDKi under study in this setting https://t.co/HcumvQml68
-
-
Mashup Score: 2
MDA, Updates on Advanced Breast Cancer: Local Management and Other New Perspectives 2023, 5/12/2023 7:30:00 AM – 5/13/2023 5:30:00 PM, This educational activity aims to enhance the knowledge of oncologists in the management of advanced breast cancer and how to implement the emerging therapies and cutting edge techniques into day-to-day practice. This activity will present the latest research…
Source: mdanderson.cloud-cme.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @naborala: https://t.co/xdVRiQQANQ https://t.co/R0vE6tx9GL
-
-
Mashup Score: 0CCNE1 and PLK1 mediates resistance to palbociclib in HR+/HER2- metastatic breast cancer - 1 year(s) ago
Abstract. Purpose: In HR+/HER2- metastatic breast cancer (MBC) is imperative to identify patients who respond poorly to CDK4/6i and to discover therapeutic targets to reverse this resistance. Non-luminal breast cancer subtype and high levels of CCNE1 are candidate biomarkers in this setting but further validation is needed. Experimental Design: We performed mRNA gene expression profiling and…
Categories: Hem/Oncs, Latest HeadlinesTweet-
CCNE1 and PLK1 mediates resistance to palbociclib in HR+/HER2- metastatic breast cancer. Weare currently studying PLK1 inhibition in patients with refractory tnbc @DFCI_BreastOnc https://t.co/HTrnoSz1rd
-
-
Mashup Score: 0Genomic characterisation of hormone receptor-positive breast cancer arising in very young women - 1 year(s) ago
Very young premenopausal women diagnosed with hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer (EBC) have higher rates of recurrence and death for reasons that remain largely unexplained.
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
One more attempt to justify the poorer outcomes of young women with breast cancer. Genomic features of HRD, PIK3CA mutations with CN-amplifications, and CN-amplifications are enriched in very young women https://t.co/c87tlNepxo
-
Genomic spectrum of actionable alterations in serial cfDNA analysis of patients with MBC. New alterations with a potential impact on treatment selection continued to emerge, particularly for patients with HR+/HER2- #bcsm https://t.co/Cg2HjBpvAU